Background: This study will systematically investigate the efficacy and safety of methylprednisolone for treatment of persistent vertigo (PV).
Methods: All following electronic databases will be searched from inception to the June 30, 2019 without language restrictions: MEDILINE, EMBASE, Cochrane Library, Web of Science, and Chinese Biomedical Literature Database. All randomized controlled trials focusing on assessing the efficacy and safety of methylprednisolone for patients with PV will be fully considered for inclusion. Cochrane risk of bias tool will be used for assessing methodological quality, and RevMan 5.3 software (Cochrane Community, London, UK) will be utilized for statistical analysis.
Results: This study will assess the efficacy and safety of methylprednisolone for PV via assessing primary outcome of vertigo, and secondary outcomes of somatization, depression, anxiety, health-related quality of life, and adverse events.
Conclusion: This study will provide a high-quality evidence to judge whether methylprednisolone is an effective and safety therapy for patients with PV.
Dissemination and ethics: No individual data will be utilized in this study, thus, it does not need ethical approval. The results of this study will be published at peer-reviewed journals.
Systematic review registration: PROSPERO CRD42019138890.